On June 29, 2026, the FDA issued its semiannual update to the List of Off-Patent, Off-Exclusivity Drugs without an Approved Generic. The document tracks approved new drug application (NDA) products that no longer hold patents or exclusivities yet still lack an approved abbreviated new drug application (ANDA). Since 2017, the agency has released the list every June and December. It now appears in two versions, prescription and over-the-counter, each broken into three sections: Part I for drugs immediately eligible for ANDA submission, Part II for those facing potential legal, regulatory, or scientific complexity, and an Appendix identifying items removed once an ANDA gained approval. Both Rx and OTC versions for June 2026 are posted as PDFs and Excel files.
More than a catalog, the list signals transparency for developers and investors searching low-competition markets. Each release effectively charts where generic launches have not followed patent expiry. For smaller manufacturers, Part I functions as a ready queue, products that can move forward without prior FDA engagement. And for payers and PBMs, long-standing entries reveal categories still exposed to brand-level pricing absent new competition. Viewed this way, the June 2026 version becomes both a field guide to market opportunity and a measure of where the generic pipeline trails.
The next list, expected in December 2026, will indicate whether developers have advanced. A larger Appendix would point to renewed ANDA activity and contraction of single-source categories. If the shift is minimal, bottlenecks, scientific or economic, may still be holding challengers back even in this off-exclusivity segment. Either result will feed directly into payer modeling and generic investment outlooks going into 2027. And after that, the pattern continues.
